Moleculin Biotech (MBRX) Competitors

$2.39 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$2.44 +0.05 (+2.09%)

As of 05/22/2026 07:57 PM Eastern

MBRX vs. ZYBT, NBRV, ELUT, INCR, and ATOS

Should you buy Moleculin Biotech stock or one of its competitors? MarketBeat compares Moleculin Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Moleculin Biotech include Zhengye Biotechnology (ZYBT), Nabriva Therapeutics (NBRV), Elutia (ELUT), InterCure (INCR), and Atossa Genetics (ATOS). These companies are all part of the "pharmaceutical products" industry.

How does Moleculin Biotech compare to Zhengye Biotechnology?

Zhengye Biotechnology (NASDAQ:ZYBT) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
Moleculin Biotech	N/A	N/A	-70.93%

Zhengye Biotechnology has a beta of -2.47, meaning that its stock price is 347% less volatile than the broader market. Comparatively, Moleculin Biotech has a beta of 1.74, meaning that its stock price is 74% more volatile than the broader market.

15.5% of Moleculin Biotech shares are held by institutional investors. 1.1% of Moleculin Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Moleculin Biotech has a consensus price target of $22.00, suggesting a potential upside of 820.50%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Moleculin Biotech is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Zhengye Biotechnology has higher revenue and earnings than Moleculin Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$16.64M	2.47	-$9.98M	N/A	N/A
Moleculin Biotech	N/A	N/A	-$33.56M	-$17.98	N/A

In the previous week, Moleculin Biotech had 5 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 5 mentions for Moleculin Biotech and 0 mentions for Zhengye Biotechnology. Zhengye Biotechnology's average media sentiment score of 0.00 beat Moleculin Biotech's score of -0.40 indicating that Zhengye Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Zhengye Biotechnology	Neutral
Moleculin Biotech	Neutral

Summary

Moleculin Biotech beats Zhengye Biotechnology on 7 of the 11 factors compared between the two stocks.

How does Moleculin Biotech compare to Nabriva Therapeutics?

Moleculin Biotech (NASDAQ:MBRX) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Moleculin Biotech has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Moleculin Biotech's return on equity of 0.00% beat Nabriva Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech	N/A	N/A	-70.93%
Nabriva Therapeutics	-148.11%	-365.53%	-135.81%

Moleculin Biotech has higher earnings, but lower revenue than Nabriva Therapeutics. Moleculin Biotech is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech	N/A	N/A	-$33.56M	-$17.98	N/A
Nabriva Therapeutics	$35.59M	0.00	-$57.19M	-$19.20	N/A

Moleculin Biotech has a beta of 1.74, meaning that its stock price is 74% more volatile than the broader market. Comparatively, Nabriva Therapeutics has a beta of 1.53, meaning that its stock price is 53% more volatile than the broader market.

Moleculin Biotech presently has a consensus price target of $22.00, suggesting a potential upside of 820.50%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, equities analysts plainly believe Moleculin Biotech is more favorable than Nabriva Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Nabriva Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

15.5% of Moleculin Biotech shares are owned by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are owned by institutional investors. 1.1% of Moleculin Biotech shares are owned by company insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Moleculin Biotech had 5 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 5 mentions for Moleculin Biotech and 0 mentions for Nabriva Therapeutics. Nabriva Therapeutics' average media sentiment score of 0.00 beat Moleculin Biotech's score of -0.40 indicating that Nabriva Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Moleculin Biotech	Neutral
Nabriva Therapeutics	Neutral

Summary

Moleculin Biotech beats Nabriva Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Moleculin Biotech compare to Elutia?

Elutia (NASDAQ:ELUT) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

74.0% of Elutia shares are owned by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are owned by institutional investors. 27.6% of Elutia shares are owned by insiders. Comparatively, 1.1% of Moleculin Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Elutia currently has a consensus target price of $6.00, suggesting a potential upside of 417.24%. Moleculin Biotech has a consensus target price of $22.00, suggesting a potential upside of 820.50%. Given Moleculin Biotech's higher probable upside, analysts clearly believe Moleculin Biotech is more favorable than Elutia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elutia	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Elutia has higher revenue and earnings than Moleculin Biotech. Moleculin Biotech is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elutia	$12.29M	4.04	$53.38M	$0.86	1.35
Moleculin Biotech	N/A	N/A	-$33.56M	-$17.98	N/A

Elutia has a net margin of 312.09% compared to Moleculin Biotech's net margin of 0.00%.

Company	Net Margins	Return on Equity	Return on Assets
Elutia	312.09%	N/A	-53.97%
Moleculin Biotech	N/A	N/A	-70.93%

Elutia has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market. Comparatively, Moleculin Biotech has a beta of 1.74, meaning that its stock price is 74% more volatile than the broader market.

In the previous week, Moleculin Biotech had 5 more articles in the media than Elutia. MarketBeat recorded 5 mentions for Moleculin Biotech and 0 mentions for Elutia. Elutia's average media sentiment score of 0.00 beat Moleculin Biotech's score of -0.40 indicating that Elutia is being referred to more favorably in the media.

Company	Overall Sentiment
Elutia	Neutral
Moleculin Biotech	Neutral

Summary

Elutia beats Moleculin Biotech on 10 of the 14 factors compared between the two stocks.

How does Moleculin Biotech compare to InterCure?

Moleculin Biotech (NASDAQ:MBRX) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

In the previous week, Moleculin Biotech had 5 more articles in the media than InterCure. MarketBeat recorded 5 mentions for Moleculin Biotech and 0 mentions for InterCure. InterCure's average media sentiment score of 0.00 beat Moleculin Biotech's score of -0.40 indicating that InterCure is being referred to more favorably in the news media.

Company	Overall Sentiment
Moleculin Biotech	Neutral
InterCure	Neutral

InterCure has higher revenue and earnings than Moleculin Biotech. Moleculin Biotech is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech	N/A	N/A	-$33.56M	-$17.98	N/A
InterCure	$78.47M	0.61	-$10.37M	$0.03	29.30

15.5% of Moleculin Biotech shares are owned by institutional investors. Comparatively, 8.3% of InterCure shares are owned by institutional investors. 1.1% of Moleculin Biotech shares are owned by insiders. Comparatively, 0.2% of InterCure shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Moleculin Biotech presently has a consensus price target of $22.00, indicating a potential upside of 820.50%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Moleculin Biotech is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Moleculin Biotech has a beta of 1.74, indicating that its share price is 74% more volatile than the broader market. Comparatively, InterCure has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech	N/A	N/A	-70.93%
InterCure	N/A	N/A	N/A

Summary

Moleculin Biotech beats InterCure on 7 of the 13 factors compared between the two stocks.

How does Moleculin Biotech compare to Atossa Genetics?

Atossa Genetics (NASDAQ:ATOS) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

Atossa Genetics currently has a consensus price target of $36.33, indicating a potential upside of 632.53%. Moleculin Biotech has a consensus price target of $22.00, indicating a potential upside of 820.50%. Given Moleculin Biotech's higher probable upside, analysts clearly believe Moleculin Biotech is more favorable than Atossa Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Atossa Genetics has a beta of 1.25, indicating that its share price is 25% more volatile than the broader market. Comparatively, Moleculin Biotech has a beta of 1.74, indicating that its share price is 74% more volatile than the broader market.

Atossa Genetics is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.21	N/A
Moleculin Biotech	N/A	N/A	-$33.56M	-$17.98	N/A

Moleculin Biotech's return on equity of 0.00% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-84.91%	-72.36%
Moleculin Biotech	N/A	N/A	-70.93%

12.7% of Atossa Genetics shares are held by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are held by institutional investors. 9.8% of Atossa Genetics shares are held by company insiders. Comparatively, 1.1% of Moleculin Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Moleculin Biotech had 2 more articles in the media than Atossa Genetics. MarketBeat recorded 5 mentions for Moleculin Biotech and 3 mentions for Atossa Genetics. Moleculin Biotech's average media sentiment score of -0.40 beat Atossa Genetics' score of -0.74 indicating that Moleculin Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atossa Genetics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Negative
Moleculin Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Moleculin Biotech beats Atossa Genetics on 9 of the 13 factors compared between the two stocks.

Get Moleculin Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MBRX vs. The Competition

Export

Metric	Moleculin Biotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$12.75M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-0.13	18.74	21.00	25.66
Price / Sales	N/A	323.98	558.19	86.31
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	0.84	7.09	10.40	7.14
Net Income	-$33.56M	$24.45M	$3.57B	$335.98M
7 Day Performance	1.70%	6.38%	6.40%	4.11%
1 Month Performance	-5.91%	2.43%	3.55%	2.52%
1 Year Performance	-89.95%	62.98%	34.13%	35.04%

Moleculin Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MBRX Moleculin Biotech	2.3893 of 5 stars	$2.39 flat	$22.00 +820.5%	-89.9%	$12.75M	N/A	N/A	20
ZYBT Zhengye Biotechnology	N/A	$0.96 -5.0%	N/A	-89.8%	$45.46M	$116.36M	N/A	278	Gap Down
NBRV Nabriva Therapeutics	N/A	N/A	N/A	N/A	$45.46M	$35.59M	N/A	70
ELUT Elutia	2.6233 of 5 stars	$1.05 flat	$6.00 +471.4%	-32.6%	$44.92M	$12.29M	1.28	180	Gap Up
INCR InterCure	0.5401 of 5 stars	$0.82 +1.2%	N/A	-43.3%	$44.84M	$270.20M	27.33	350	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MBRX) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Moleculin Biotech (MBRX) Competitors

MBRX vs. ZYBT, NBRV, ELUT, INCR, and ATOS

How does Moleculin Biotech compare to Zhengye Biotechnology?

Summary

How does Moleculin Biotech compare to Nabriva Therapeutics?

Summary

How does Moleculin Biotech compare to Elutia?

Summary

How does Moleculin Biotech compare to InterCure?

Summary

How does Moleculin Biotech compare to Atossa Genetics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBRX vs. The Competition

Moleculin Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Moleculin Biotech (MBRX) Competitors

MBRX vs. ZYBT, NBRV, ELUT, INCR, and ATOS

How does Moleculin Biotech compare to Zhengye Biotechnology?

Is ZYBT or MBRX more profitable?

Which has more volatility and risk, ZYBT or MBRX?

Do institutionals and insiders have more ownership in ZYBT or MBRX?

Do analysts rate ZYBT or MBRX?

Which has preferable earnings and valuation, ZYBT or MBRX?

Does the media prefer ZYBT or MBRX?

Summary

How does Moleculin Biotech compare to Nabriva Therapeutics?

Is MBRX or NBRV more profitable?

Which has stronger valuation & earnings, MBRX or NBRV?

Which has more risk and volatility, MBRX or NBRV?

Do analysts prefer MBRX or NBRV?

Do institutionals & insiders hold more shares of MBRX or NBRV?

Does the media refer more to MBRX or NBRV?

Summary

How does Moleculin Biotech compare to Elutia?

Do institutionals and insiders hold more shares of ELUT or MBRX?

Do analysts prefer ELUT or MBRX?

Which has better earnings and valuation, ELUT or MBRX?

Is ELUT or MBRX more profitable?

Which has more volatility and risk, ELUT or MBRX?

Does the media refer more to ELUT or MBRX?

Summary

How does Moleculin Biotech compare to InterCure?

Does the media favor MBRX or INCR?

Which has stronger earnings & valuation, MBRX or INCR?

Do insiders and institutionals hold more shares of MBRX or INCR?

Do analysts prefer MBRX or INCR?

Which has more risk & volatility, MBRX or INCR?

Is MBRX or INCR more profitable?

Summary

How does Moleculin Biotech compare to Atossa Genetics?

Do analysts prefer ATOS or MBRX?

Which has more risk & volatility, ATOS or MBRX?

Which has better valuation and earnings, ATOS or MBRX?

Is ATOS or MBRX more profitable?

Do insiders & institutionals believe in ATOS or MBRX?

Does the media refer more to ATOS or MBRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBRX vs. The Competition

Moleculin Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools